Aries Wealth Management Purchases 168 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Aries Wealth Management increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,096 shares of the company’s stock after purchasing an additional 168 shares during the quarter. Aries Wealth Management’s holdings in IDEXX Laboratories were worth $1,300,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of IDXX. Hurley Capital LLC bought a new position in IDEXX Laboratories in the 4th quarter valued at about $29,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories in the 4th quarter valued at about $30,000. Colonial Trust Co SC raised its holdings in IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock valued at $35,000 after acquiring an additional 39 shares during the period. Kestra Investment Management LLC bought a new position in IDEXX Laboratories in the 4th quarter valued at about $38,000. Finally, Itau Unibanco Holding S.A. raised its holdings in IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock valued at $40,000 after acquiring an additional 81 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $522.70 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $42.04 billion, a price-to-earnings ratio of 48.99, a P/E/G ratio of 3.41 and a beta of 1.55. The firm’s 50 day simple moving average is $473.11 and its 200 day simple moving average is $444.45. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $530.73.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted $2.71 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Morgan Stanley raised their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a report on Monday, May 5th. Leerink Partners raised their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Stifel Nicolaus raised their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a “hold” rating in a report on Monday, May 19th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $546.00.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director now owns 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.98% of the stock is currently owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.